{ "schemaVersion": 1, "organisationId": "O-ae5455d79dcf4d8a9a29baa4f5eaa83a", "slug": "irhythm-technologies-inc", "name": "iRhythm Technologies, Inc.", "updatedAt": "2026-10-02T13:52:49.219603Z", "sections": [ { "type": "OVERVIEW", "text": "iRhythm Technologies, Inc. is a digital health and medical technology company focused on cardiac rhythm monitoring. Its core Zio service combines a prescription ECG patch with software-based analysis and a report for the prescribing physician; the Zio monitor records ECG continuously for up to 14 days. [P62613382] The company’s stated mission is to create trusted solutions to detect and prevent disease. [https://www.irhythmtech.com/us/en/who-we-are/trust-center]\n\nFounded in 2006 and headquartered in San Francisco, iRhythm reported $747.1 million in revenue for 2025 and approximately 2,400 regular full-time employees at year-end. [P23214428][P64115874] Its business is primarily centered on the U.S., with Zio service launched in Japan in 2025; the company also reported facilities in the United States, Manila, and London. [https://investors.irhythmtech.com/news/news-details/2025/iRhythm-Launches-Zio-Long-Term-Continuous-Monitoring-Service-in-Japan-as-the-Zio-ECG-Recording-and-Analysis-System-Advancing-AI-Powered-Arrhythmia-Detection/default.aspx][T275050]\n[P62613382][https://www.irhythmtech.com/us/en/who-we-are/trust-center][P23214428][P64115874][https://investors.irhythmtech.com/news/news-details/2025/iRhythm-Launches-Zio-Long-Term-Continuous-Monitoring-Service-in-Japan-as-the-Zio-ECG-Recording-and-Analysis-System-Advancing-AI-Powered-Arrhythmia-Detection/default.aspx][T275050][https://www.irhythmtech.com/us/en/who-we-are/trust-center][https://investors.irhythmtech.com/news/news-details/2025/iRhythm-Launches-Zio-Long-Term-Continuous-Monitoring-Service-in-Japan-as-the-Zio-ECG-Recording-and-Analysis-System-Advancing-AI-Powered-Arrhythmia-Detection/default.aspx]", "updatedAt": "2026-10-02T13:52:49.219603Z" }, { "type": "PRODUCTS", "text": "iRhythm’s Zio monitor is a prescription-only wearable ECG patch that records heart activity continuously for up to 14 days. After the wear period, its ZEUS software analyzes the recorded ECG for specified arrhythmias, and a report is provided electronically to the prescribing physician. The current Zio monitor is described as 72% smaller, 62% lighter, and 23% thinner than the prior-generation Zio XT; it also has breathable adhesive, Bluetooth connectivity, and improved processing efficiency. Zio XT is the previous-generation patch monitor, also designed for continuous recording for up to 14 days. [P62613382][P106531874][P33245069]\n\nZio AT combines a prescription ECG patch, which records continuously for up to 14 days, with a wireless gateway that connects the patch to ZEUS during wear and transmits data to the cloud over LTE. iRhythm’s monitoring services include long-term continuous monitoring, short-term continuous monitoring, and mobile cardiac telemetry. For long-term monitoring, the patch can capture about 1.5 million heartbeats over up to 14 consecutive days; ZEUS-detected events and technician analysis contribute to a comprehensive end-of-wear report. [P37981510][P150395244][P66747415] A 2025 investor presentation described proposed Zio MCT features including up to 21-day wear and enhanced detection and reporting, but stated that the product was not yet FDA-cleared at that time. [T19731626][P196069388] The cited filing reports revenue growth for Zio monitor and Zio AT together but does not give individual product revenue shares. [P150395557]\n[P62613382][P106531874][P33245069][P37981510][P150395244][P66747415][T19731626][P196069388][P150395557]", "updatedAt": "2026-10-02T13:52:49.219603Z" }, { "type": "GEOGRAPHY", "text": "iRhythm Technologies’ operations are centered in the United States, with its headquarters and clinical center in San Francisco and a manufacturing facility in Cypress, California. It also lists clinical centers in Deerfield, Illinois; Houston, Texas; and Manila, Philippines, and corporate office space in Solana Beach, California, and London, UK. [P87239981]\n\nOutside the US, the company describes commercial activity in the UK, selected European countries, and Japan. Its small direct European sales team covers Switzerland, Austria, and the Netherlands; distribution arrangements support Spain and other European markets. In the UK, it has a small direct sales and clinical infrastructure in Bagshot, Surrey. Japan sales and fulfillment use a third-party distributor, and the company launched its service there in May 2025. [P56762977] [P15186887] [https://investors.irhythmtech.com/news/news-details/2025/iRhythm-Launches-Zio-Long-Term-Continuous-Monitoring-Service-in-Japan-as-the-Zio-ECG-Recording-and-Analysis-System-Advancing-AI-Powered-Arrhythmia-Detection/default.aspx] FY2025 reporting does not provide revenue by country or region; it describes the business as one reporting unit. [P16411851]\n[P87239981][P56762977][P15186887][https://investors.irhythmtech.com/news/news-details/2025/iRhythm-Launches-Zio-Long-Term-Continuous-Monitoring-Service-in-Japan-as-the-Zio-ECG-Recording-and-Analysis-System-Advancing-AI-Powered-Arrhythmia-Detection/default.aspx][P16411851][https://investors.irhythmtech.com/news/news-details/2025/iRhythm-Launches-Zio-Long-Term-Continuous-Monitoring-Service-in-Japan-as-the-Zio-ECG-Recording-and-Analysis-System-Advancing-AI-Powered-Arrhythmia-Detection/default.aspx]", "updatedAt": "2026-10-02T13:52:49.219603Z" }, { "type": "SEGMENTS", "text": "iRhythm Technologies reports one operating and reportable segment: its global ambulatory cardiac monitoring business. The company’s offerings within this segment include long-term continuous cardiac monitoring and mobile cardiac telemetry services used to detect and diagnose arrhythmias. These offerings are not reported as separate segments. [P81624133][P66747415]\n\nThe single reportable segment represents 100% of reported company revenue; the company does not disclose revenue contributions for separate product or service segments. Its 2026 second-quarter filing confirms the one-segment structure. [P150395289]\n[P81624133][P66747415][P150395289]", "updatedAt": "2026-10-02T13:52:49.219603Z" }, { "type": "HISTORY", "text": "iRhythm Technologies was founded in 2006 by Dr. Uday N. Kumar, who developed the company out of Stanford Biodesign’s Innovation Fellowship. [https://med.stanford.edu/biodesign/our-impact/technologies/irhythm.html] Its Zio Patch received FDA clearance in 2009 and entered U.S. commercial launch in 2011; in 2010, iRhythm also announced a co-marketing partnership with St. Jude Medical. [https://www.fiercebiotech.com/medical-devices/irhythm-has-ce-mark-sight-for-arrhythmia-dx-patch] [https://www.prnewswire.com/news-releases/st-jude-medical-and-irhythm-technologies-enter-into-partnership-to-co-market-novel-cardiac-rhythm-monitor-93632259.html]\n\nThe company went public in October 2016, and the FDA cleared its Zio AT ECG Monitoring System in 2017. [https://investors.irhythmtech.com/news/news-details/2016/iRhythm-Technologies-Announces-Pricing-of-Initial-Public-Offering/default.aspx] [https://www.accessdata.fda.gov/cdrh_docs/pdf16/K163512.pdf] After a series of CEO transitions in 2020–21, Quentin Blackford became president and CEO in October 2021. [https://investors.irhythmtech.com/news/news-details/2020/iRhythm-Technologies-President-and-CEO-Kevin-King-to-Retire-Michael-Coyle-Joins-Company-as-President-and-CEO-Effective-January-12-2021/default.aspx] [https://investors.irhythmtech.com/news/news-details/2021/iRhythm-Technologies-Announces-Leadership-Transition/default.aspx] [https://investors.irhythmtech.com/news/news-details/2021/iRhythm-Technologies-Names-Quentin-Blackford-President-and-Chief-Executive-Officer/default.aspx] In 2023, iRhythm launched a next-generation Zio monitor and enhanced service. [https://investors.irhythmtech.com/news/news-details/2023/iRhythm-Launches-Next-Generation-Zio-Monitor-and-Enhanced-Zio-Service-Its-Smallest-Lightest-and-Thinnest-Cardiac-Monitor/default.aspx] In 2026, it completed a holding-company reorganization, with iRhythm Holdings becoming successor registrant, and announced a proposed acquisition of VitalConnect. [P34085353] [https://investors.irhythmtech.com/news/news-details/2026/iRhythm-to-Acquire-VitalConnect-Expanding-Its-Cardiac-Monitoring-Platform-Across-Ambulatory-Inpatient-and-Hospital-to-Home-Care/default.aspx]\n[P34085353][https://med.stanford.edu/biodesign/our-impact/technologies/irhythm.html][https://www.fiercebiotech.com/medical-devices/irhythm-has-ce-mark-sight-for-arrhythmia-dx-patch][https://www.prnewswire.com/news-releases/st-jude-medical-and-irhythm-technologies-enter-into-partnership-to-co-market-novel-cardiac-rhythm-monitor-93632259.html][https://investors.irhythmtech.com/news/news-details/2016/iRhythm-Technologies-Announces-Pricing-of-Initial-Public-Offering/default.aspx][https://www.accessdata.fda.gov/cdrh_docs/pdf16/K163512.pdf][https://investors.irhythmtech.com/news/news-details/2020/iRhythm-Technologies-President-and-CEO-Kevin-King-to-Retire-Michael-Coyle-Joins-Company-as-President-and-CEO-Effective-January-12-2021/default.aspx][https://investors.irhythmtech.com/news/news-details/2021/iRhythm-Technologies-Announces-Leadership-Transition/default.aspx][https://investors.irhythmtech.com/news/news-details/2021/iRhythm-Technologies-Names-Quentin-Blackford-President-and-Chief-Executive-Officer/default.aspx][https://investors.irhythmtech.com/news/news-details/2023/iRhythm-Launches-Next-Generation-Zio-Monitor-and-Enhanced-Zio-Service-Its-Smallest-Lightest-and-Thinnest-Cardiac-Monitor/default.aspx][https://investors.irhythmtech.com/news/news-details/2026/iRhythm-to-Acquire-VitalConnect-Expanding-Its-Cardiac-Monitoring-Platform-Across-Ambulatory-Inpatient-and-Hospital-to-Home-Care/default.aspx]", "updatedAt": "2026-10-02T13:52:49.219603Z" } ], "sources": [ { "id": "P62613382", "href": "https://app.finbar.com/go?id=P62613382", "label": "iRhythm Technologies, Inc. — Full financial report (2025 Y)", "documentId": "D-37e0d3e75dd54815ae2f9a80de4a8428" }, { "id": "https://www.irhythmtech.com/us/en/who-we-are/trust-center", "href": "https://www.irhythmtech.com/us/en/who-we-are/trust-center", "label": "www.irhythmtech.com" }, { "id": "P23214428", "href": "https://app.finbar.com/go?id=P23214428", "label": "iRhythm Technologies, Inc. — Full financial report (2025 Y)", "documentId": "D-37e0d3e75dd54815ae2f9a80de4a8428" }, { "id": "P64115874", "href": "https://app.finbar.com/go?id=P64115874", "label": "iRhythm Technologies, Inc. — Full financial report (2025 Y)", "documentId": "D-37e0d3e75dd54815ae2f9a80de4a8428" }, { "id": "https://investors.irhythmtech.com/news/news-details/2025/iRhythm-Launches-Zio-Long-Term-Continuous-Monitoring-Service-in-Japan-as-the-Zio-ECG-Recording-and-Analysis-System-Advancing-AI-Powered-Arrhythmia-Detection/default.aspx", "href": "https://investors.irhythmtech.com/news/news-details/2025/iRhythm-Launches-Zio-Long-Term-Continuous-Monitoring-Service-in-Japan-as-the-Zio-ECG-Recording-and-Analysis-System-Advancing-AI-Powered-Arrhythmia-Detection/default.aspx", "label": "investors.irhythmtech.com" }, { "id": "T275050", "href": "https://app.finbar.com/go?id=T275050", "label": "iRhythm Technologies, Inc. — Full financial report (2025 Y)", "documentId": "D-37e0d3e75dd54815ae2f9a80de4a8428" }, { "id": "P106531874", "href": "https://app.finbar.com/go?id=P106531874", "label": "iRhythm Technologies, Inc. — Full financial report (2025 Y)", "documentId": "D-37e0d3e75dd54815ae2f9a80de4a8428" }, { "id": "P33245069", "href": "https://app.finbar.com/go?id=P33245069", "label": "iRhythm Technologies, Inc. — Full financial report (2025 Y)", "documentId": "D-37e0d3e75dd54815ae2f9a80de4a8428" }, { "id": "P37981510", "href": "https://app.finbar.com/go?id=P37981510", "label": "iRhythm Technologies, Inc. — Full financial report (2025 Y)", "documentId": "D-37e0d3e75dd54815ae2f9a80de4a8428" }, { "id": "P150395244", "href": "https://app.finbar.com/go?id=P150395244", "label": "iRhythm Technologies, Inc. — Full financial report (2026 Q 2)", "documentId": "D-483aff398bde4f4798a37851029501b3" }, { "id": "P66747415", "href": "https://app.finbar.com/go?id=P66747415", "label": "iRhythm Technologies, Inc. — Full financial report (2025 Y)", "documentId": "D-37e0d3e75dd54815ae2f9a80de4a8428" }, { "id": "T19731626", "href": "https://app.finbar.com/go?id=T19731626", "label": "iRhythm Technologies, Inc. — Presentation (2025 Y), p7", "documentId": "D-07f6d3cbdd614bf49e456ac4eaf7bd62", "page": 7 }, { "id": "P196069388", "href": "https://app.finbar.com/go?id=P196069388", "label": "iRhythm Technologies, Inc. — Presentation (2025 Y), p9", "documentId": "D-07f6d3cbdd614bf49e456ac4eaf7bd62", "page": 9 }, { "id": "P150395557", "href": "https://app.finbar.com/go?id=P150395557", "label": "iRhythm Technologies, Inc. — Full financial report (2026 Q 2)", "documentId": "D-483aff398bde4f4798a37851029501b3" }, { "id": "P87239981", "href": "https://app.finbar.com/go?id=P87239981", "label": "iRhythm Technologies, Inc. — Full financial report (2025 Y)", "documentId": "D-37e0d3e75dd54815ae2f9a80de4a8428" }, { "id": "P56762977", "href": "https://app.finbar.com/go?id=P56762977", "label": "iRhythm Technologies, Inc. — Full financial report (2025 Y)", "documentId": "D-37e0d3e75dd54815ae2f9a80de4a8428" }, { "id": "P15186887", "href": "https://app.finbar.com/go?id=P15186887", "label": "iRhythm Technologies, Inc. — Full financial report (2025 Y)", "documentId": "D-37e0d3e75dd54815ae2f9a80de4a8428" }, { "id": "P16411851", "href": "https://app.finbar.com/go?id=P16411851", "label": "iRhythm Technologies, Inc. — Full financial report (2025 Y)", "documentId": "D-37e0d3e75dd54815ae2f9a80de4a8428" }, { "id": "P81624133", "href": "https://app.finbar.com/go?id=P81624133", "label": "iRhythm Technologies, Inc. — Full financial report (2025 Y)", "documentId": "D-37e0d3e75dd54815ae2f9a80de4a8428" }, { "id": "P150395289", "href": "https://app.finbar.com/go?id=P150395289", "label": "iRhythm Technologies, Inc. — Full financial report (2026 Q 2)", "documentId": "D-483aff398bde4f4798a37851029501b3" }, { "id": "https://med.stanford.edu/biodesign/our-impact/technologies/irhythm.html", "href": "https://med.stanford.edu/biodesign/our-impact/technologies/irhythm.html", "label": "med.stanford.edu" }, { "id": "https://www.fiercebiotech.com/medical-devices/irhythm-has-ce-mark-sight-for-arrhythmia-dx-patch", "href": "https://www.fiercebiotech.com/medical-devices/irhythm-has-ce-mark-sight-for-arrhythmia-dx-patch", "label": "www.fiercebiotech.com" }, { "id": "https://www.prnewswire.com/news-releases/st-jude-medical-and-irhythm-technologies-enter-into-partnership-to-co-market-novel-cardiac-rhythm-monitor-93632259.html", "href": "https://www.prnewswire.com/news-releases/st-jude-medical-and-irhythm-technologies-enter-into-partnership-to-co-market-novel-cardiac-rhythm-monitor-93632259.html", "label": "www.prnewswire.com" }, { "id": "https://investors.irhythmtech.com/news/news-details/2016/iRhythm-Technologies-Announces-Pricing-of-Initial-Public-Offering/default.aspx", "href": "https://investors.irhythmtech.com/news/news-details/2016/iRhythm-Technologies-Announces-Pricing-of-Initial-Public-Offering/default.aspx", "label": "investors.irhythmtech.com" }, { "id": "https://www.accessdata.fda.gov/cdrh_docs/pdf16/K163512.pdf", "href": "https://www.accessdata.fda.gov/cdrh_docs/pdf16/K163512.pdf", "label": "www.accessdata.fda.gov" }, { "id": "https://investors.irhythmtech.com/news/news-details/2020/iRhythm-Technologies-President-and-CEO-Kevin-King-to-Retire-Michael-Coyle-Joins-Company-as-President-and-CEO-Effective-January-12-2021/default.aspx", "href": "https://investors.irhythmtech.com/news/news-details/2020/iRhythm-Technologies-President-and-CEO-Kevin-King-to-Retire-Michael-Coyle-Joins-Company-as-President-and-CEO-Effective-January-12-2021/default.aspx", "label": "investors.irhythmtech.com" }, { "id": "https://investors.irhythmtech.com/news/news-details/2021/iRhythm-Technologies-Announces-Leadership-Transition/default.aspx", "href": "https://investors.irhythmtech.com/news/news-details/2021/iRhythm-Technologies-Announces-Leadership-Transition/default.aspx", "label": "investors.irhythmtech.com" }, { "id": "https://investors.irhythmtech.com/news/news-details/2021/iRhythm-Technologies-Names-Quentin-Blackford-President-and-Chief-Executive-Officer/default.aspx", "href": "https://investors.irhythmtech.com/news/news-details/2021/iRhythm-Technologies-Names-Quentin-Blackford-President-and-Chief-Executive-Officer/default.aspx", "label": "investors.irhythmtech.com" }, { "id": "https://investors.irhythmtech.com/news/news-details/2023/iRhythm-Launches-Next-Generation-Zio-Monitor-and-Enhanced-Zio-Service-Its-Smallest-Lightest-and-Thinnest-Cardiac-Monitor/default.aspx", "href": "https://investors.irhythmtech.com/news/news-details/2023/iRhythm-Launches-Next-Generation-Zio-Monitor-and-Enhanced-Zio-Service-Its-Smallest-Lightest-and-Thinnest-Cardiac-Monitor/default.aspx", "label": "investors.irhythmtech.com" }, { "id": "P34085353", "href": "https://app.finbar.com/go?id=P34085353", "label": "iRhythm Technologies, Inc. — Press release (2025 Y)", "documentId": "D-74627edf181b4efaaefe045b7b6a6bca" }, { "id": "https://investors.irhythmtech.com/news/news-details/2026/iRhythm-to-Acquire-VitalConnect-Expanding-Its-Cardiac-Monitoring-Platform-Across-Ambulatory-Inpatient-and-Hospital-to-Home-Care/default.aspx", "href": "https://investors.irhythmtech.com/news/news-details/2026/iRhythm-to-Acquire-VitalConnect-Expanding-Its-Cardiac-Monitoring-Platform-Across-Ambulatory-Inpatient-and-Hospital-to-Home-Care/default.aspx", "label": "investors.irhythmtech.com" } ] }